Ono Pharmaceutical (OTCMKTS:OPHLF) Trading 9.2% Higher – Should You Buy?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) traded up 9.2% on Monday . The company traded as high as $14.61 and last traded at $14.61. 212 shares were traded during trading, a decline of 52% from the average daily volume of 438 shares. The stock had previously closed at $13.38.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has an average rating of “Strong Buy”.

Ono Pharmaceutical Stock Performance

The company has a market capitalization of $6.87 billion, a P/E ratio of 14.76 and a beta of 0.34. The company’s 50 day moving average is $14.32 and its 200-day moving average is $14.74. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.